Search

Your search keyword '"Shah, Mithun Vinod"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Shah, Mithun Vinod" Remove constraint Author: "Shah, Mithun Vinod" Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
17 results on '"Shah, Mithun Vinod"'

Search Results

1. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.

2. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.

3. Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.

4. Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.

5. Characteristics and prognosis of mutated STAG2 myeloid neoplasms.

7. Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.

9. A population-based study of chronic neutrophilic leukemia in the United States: 2004 to 2015.

10. Discrepancy of blast percentage between the bone marrow aspirate and biopsy and its impact on survival outcomes in patients with myelodysplastic syndromes excess blast (MDS-EB).

11. Pyridoxine impact on patients with myelodysplastic syndromes with ring sideroblasts: Single institution retrospective study.

12. The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.

13. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines

14. Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.

Catalog

Books, media, physical & digital resources